よむ、つかう、まなぶ。
【参考資料5】抗微生物薬適正使用の手引き 第三版 別冊 (46 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
別冊
141. Araoka H, Fujii T, Izutsu K. et al. Rapidly progressive fatal hemorrhagic pneumonia caused
by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis. 2012
Aug;14(4):355-363.
142. EUCAST Clinical Breakpoints v 13.0.
143. Cairo J, Hachem R, Rangaraj G, Granwehr B, Raad I. Predictors of catheter-related gramnegative bacilli bacteraemia among cancer patients. Clin Microbiol Infect. 2011
Nov;17(11):1711-1716.
144. Mojica MF, Humphries R, Lipuma JJ. et al. Clinical challenges treating Stenotrophomonas
maltophilia infections: an update. JAC Antimicrob Resist. 2022 May;4(3):dlac040.
145. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With
Antibiotic Use in Hospitalized Patients. JAMA Intern Med. 2017 Sep;177(9):1308-1315.
146. Cho SY, Kang CI, Kim J. et al. Can levofloxacin be a useful alternative to trimethoprimsulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents
Chemother. 2014;58(1):581-3.
147. Nys C, Cherabuddi K, Venugopalan V, Klinker KP. Clinical and Microbiologic Outcomes in
Patients with Monomicrobial Stenotrophomonas maltophilia Infections. Antimicrob Agents
Chemother. 2019 Oct;63(11):e00788-19.
148. Shah MD, Coe KE, El Boghdadly Z. et al. Efficacy of combination therapy versus
monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. J Antimicrob
Chemother. 2019 Jul;74(7):2055-2059.
149. 石井良和. 薬剤感受性試験とブレイクポイント，その問題点と今後の展望. 日本化学療法学会
雑誌 2011:454-9.
150. Magill SS, O'Leary E, Janelle SJ. et al. Changes in Prevalence of Health Care-Associated
Infections in U.S. Hospitals. N Engl J Med. 2018 Nov;379(18):1732-1744.
151. Marra AR, Perencevich EN, Nelson RE. et al. Incidence and Outcomes Associated With
Clostridium difficile Infections: A Systematic Review and Meta-analysis. JAMA Netw Open.
2020 Jan;3(1):e1917597.
152. Kato H, Senoh M, Honda H. et al. Clostridioides (Clostridium) difficile infection burden in
Japan: A multicenter prospective study. Anaerobe. 2019Dec;60:102011.
153. Lessa FC, Mu Y, Bamberg WM. et al. Burden of Clostridium difficile infection in the United
States. N Engl J Med. 2015 Feb;372(9):825-834.
154. Kociolek LK, Gerding DN, Carrico R. et al. Strategies to prevent Clostridioides difficile
infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023
Apr;44(4):527-549.
155. Clostridioides difficile 感染症診療ガイドライン 公益社団法人日本化学療法学会・一般社団法
人日本感染症学会 CDI 診療ガイドライン作成委員会編. 2022. at
https://www.kansensho.or.jp/uploads/files/guidelines/guideline_cdi_230125.pdf.)
156. Keessen EC, Hensgens MP, Spigaglia P. et al. Antimicrobial susceptibility profiles of human
and piglet Clostridium difficile PCR-ribotype 078. Antimicrob Resist Infect Control. 2013
Apr;2:14.
46
第三版
別冊
141. Araoka H, Fujii T, Izutsu K. et al. Rapidly progressive fatal hemorrhagic pneumonia caused
by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis. 2012
Aug;14(4):355-363.
142. EUCAST Clinical Breakpoints v 13.0.
143. Cairo J, Hachem R, Rangaraj G, Granwehr B, Raad I. Predictors of catheter-related gramnegative bacilli bacteraemia among cancer patients. Clin Microbiol Infect. 2011
Nov;17(11):1711-1716.
144. Mojica MF, Humphries R, Lipuma JJ. et al. Clinical challenges treating Stenotrophomonas
maltophilia infections: an update. JAC Antimicrob Resist. 2022 May;4(3):dlac040.
145. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With
Antibiotic Use in Hospitalized Patients. JAMA Intern Med. 2017 Sep;177(9):1308-1315.
146. Cho SY, Kang CI, Kim J. et al. Can levofloxacin be a useful alternative to trimethoprimsulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents
Chemother. 2014;58(1):581-3.
147. Nys C, Cherabuddi K, Venugopalan V, Klinker KP. Clinical and Microbiologic Outcomes in
Patients with Monomicrobial Stenotrophomonas maltophilia Infections. Antimicrob Agents
Chemother. 2019 Oct;63(11):e00788-19.
148. Shah MD, Coe KE, El Boghdadly Z. et al. Efficacy of combination therapy versus
monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. J Antimicrob
Chemother. 2019 Jul;74(7):2055-2059.
149. 石井良和. 薬剤感受性試験とブレイクポイント，その問題点と今後の展望. 日本化学療法学会
雑誌 2011:454-9.
150. Magill SS, O'Leary E, Janelle SJ. et al. Changes in Prevalence of Health Care-Associated
Infections in U.S. Hospitals. N Engl J Med. 2018 Nov;379(18):1732-1744.
151. Marra AR, Perencevich EN, Nelson RE. et al. Incidence and Outcomes Associated With
Clostridium difficile Infections: A Systematic Review and Meta-analysis. JAMA Netw Open.
2020 Jan;3(1):e1917597.
152. Kato H, Senoh M, Honda H. et al. Clostridioides (Clostridium) difficile infection burden in
Japan: A multicenter prospective study. Anaerobe. 2019Dec;60:102011.
153. Lessa FC, Mu Y, Bamberg WM. et al. Burden of Clostridium difficile infection in the United
States. N Engl J Med. 2015 Feb;372(9):825-834.
154. Kociolek LK, Gerding DN, Carrico R. et al. Strategies to prevent Clostridioides difficile
infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023
Apr;44(4):527-549.
155. Clostridioides difficile 感染症診療ガイドライン 公益社団法人日本化学療法学会・一般社団法
人日本感染症学会 CDI 診療ガイドライン作成委員会編. 2022. at
https://www.kansensho.or.jp/uploads/files/guidelines/guideline_cdi_230125.pdf.)
156. Keessen EC, Hensgens MP, Spigaglia P. et al. Antimicrobial susceptibility profiles of human
and piglet Clostridium difficile PCR-ribotype 078. Antimicrob Resist Infect Control. 2013
Apr;2:14.
46